A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants
NCT02427958
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
307
Enrollment
INDUSTRY
Sponsor class
Conditions
Central Precocious Puberty
Interventions
DRUG:
Leuprorelin
Sponsor
Takeda